STAT+: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data
Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.
In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.
This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.
Continue to STAT+ to read the full story…
